Methods These are the consensus statements and guideline of ASHP, IDSA, the Pediatric
Infectious Diseases Society (PIDS), and SIDP. Guideline panel composition consisted of …

It should be recognized that children are not small adults, hence dosing in children should
not be a 'small adult dose'. A mean population dose in all age groups is just an average …

Importance Obesity affects nearly one-sixth of US children and results in alterations to body
composition and physiology that can affect drug disposition, possibly leading to therapeutic …

Background: Our objectives were to (1) determine the pharmacokinetic indices of
vancomycin in pediatric patients; and (2) compare attainment of 2 target exposures: area …

Purpose Clinicians are increasingly likely to have under their care obese children with
diseases requiring pharmacotherapy. Optimal drug dosing for this population is unclear …

Approximately 31.8% of US children ages 2 to 19 years are considered overweight or
obese. This creates significant challenges to dosing medications that are primarily weight …

Purpose The development and use of a decision support tool to help formulate
recommendations for dosing of commonly prescribed medications in critically ill obese …

Although obesity is prevalent among children in the United States, pharmacokinetic (PK)
data for obese children are limited. Clindamycin is a commonly used antibiotic that may …

Background Vancomycin treatment failure has been associated with low serum vancomycin
trough concentrations, prompting recommendations to increase the daily doses in adults …

Vancomycin is an effective but potentially nephrotoxic antibiotic commonly used for severe
infections. Dosing guidelines for vancomycin in obese children and adolescents with or …